[
  {
    "ts": "2026-02-14T00:03:31+00:00",
    "headline": "Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference",
    "summary": "Foghorn Therapeutics (NASDAQ:FHTX) President and CEO Adrian Gottschalk said the company was built around the idea that chromatin regulation—and specifically the BAF (SWI/SNF) chromatin remodeling complex—represents a broad and clinically relevant set of oncology targets that have historically been d",
    "url": "https://www.marketbeat.com/instant-alerts/foghorn-therapeutics-ceo-talks-lilly-partnered-smarca2-phase-1-and-new-degrader-targets-at-conference-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "f6080218-ff84-31e2-890e-a98e41145b26",
      "content": {
        "id": "f6080218-ff84-31e2-890e-a98e41145b26",
        "contentType": "STORY",
        "title": "Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference",
        "description": "",
        "summary": "Foghorn Therapeutics (NASDAQ:FHTX) President and CEO Adrian Gottschalk said the company was built around the idea that chromatin regulation—and specifically the BAF (SWI/SNF) chromatin remodeling complex—represents a broad and clinically relevant set of oncology targets that have historically been d",
        "pubDate": "2026-02-14T00:03:31Z",
        "displayTime": "2026-02-14T00:03:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/b05b3478b48461b0e513811fd8a02875",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Foghorn Therapeutics logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8GOqruC.xymAnV14hbTkyQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/b05b3478b48461b0e513811fd8a02875.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AnwWbIG.xWnRqq1dYALO_g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/b05b3478b48461b0e513811fd8a02875.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/foghorn-therapeutics-ceo-talks-lilly-partnered-smarca2-phase-1-and-new-degrader-targets-at-conference-2026-02-13/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/foghorn-therapeutics-ceo-talks-lilly-000331230.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "FHTX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]